All In Biotech

NDA 021151 · Legacy

Betapace Af

Sotalol Hydrochloride · Oral

Orphan

Last checked: Nov 20, 2026Latest source record: Aug 17, 2011 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2000

Feb 22, 2000

Approved uses

1

Original approval plus efficacy supplements

Registered trials

57

14 Phase 3, 9 recruiting

FAERS reports

2,600

2,156 serious, 260 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 22, 2000 Original approval · Type 6 - New Indication (no longer used) OrphanReviewLetterLabel
6 products under this application
  • BETAPACE AF · SOTALOL HYDROCHLORIDE 40MG · TABLET, ORAL · Discontinued
  • BETAPACE AF · SOTALOL HYDROCHLORIDE 120MG · TABLET, ORAL · Prescription · TE AB
  • BETAPACE AF · SOTALOL HYDROCHLORIDE 60MG · TABLET, ORAL · Discontinued
  • BETAPACE AF · SOTALOL HYDROCHLORIDE 100MG · TABLET, ORAL · Discontinued
  • BETAPACE AF · SOTALOL HYDROCHLORIDE 160MG · TABLET, ORAL · Prescription · TE AB
  • BETAPACE AF · SOTALOL HYDROCHLORIDE 80MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Sotalol" as an intervention, any sponsor and status, largest first.

All 57 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • atrial fibrillation186
  • drug ineffective151
  • electrocardiogram qt prolonged149
  • hypotension125
  • dyspnoea119
  • dizziness116
  • bradycardia112
  • drug interaction99
  • fatigue97
  • nausea95
  • fall87
  • off label use73

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200453
200532
2006128
2007237
200843
2009128
201036
201190
2012111
201363
201470
201556
201680
201798
2018124
2019147
2020112
202195
2022142
2023152
2024194
2025254
2026155

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Betapace Af (Sotalol HCl)

2024 spending

$199K

Beneficiaries

23

112 claims

Per beneficiary

$8,658

$14.97 per unit

View as table
YearSpending
2020$432,548
2021$295,085
2022$237,965
2023$224,275
2024$199,124

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 421 on PubMed

Sponsor: Legacy

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.